Medifast (MED) to Release Earnings on Tuesday

Medifast (NYSE:MED) will likely be issuing its Q4 2025 results after the market closes on Tuesday, February 17th. Analysts expect Medifast to post earnings of ($0.80) per share and revenue of $71.40 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 4:30 PM ET.

Medifast Stock Performance

Shares of MED opened at $11.33 on Tuesday. The business’s 50-day moving average is $11.37 and its two-hundred day moving average is $12.46. The company has a market capitalization of $124.52 million, a P/E ratio of 1,133.00 and a beta of 0.53. Medifast has a fifty-two week low of $10.10 and a fifty-two week high of $16.66.

Analyst Ratings Changes

Several analysts recently commented on MED shares. Wall Street Zen raised Medifast from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Medifast in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $16.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Lido Advisors LLC purchased a new stake in Medifast in the 3rd quarter worth $4,521,000. Bank of America Corp DE grew its position in shares of Medifast by 37.4% in the second quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer’s stock valued at $5,569,000 after purchasing an additional 107,854 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Medifast in the third quarter valued at about $867,000. Bridgeway Capital Management LLC increased its stake in shares of Medifast by 104.5% during the third quarter. Bridgeway Capital Management LLC now owns 118,477 shares of the specialty retailer’s stock worth $1,620,000 after purchasing an additional 60,533 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Medifast by 19.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 298,369 shares of the specialty retailer’s stock worth $4,079,000 after purchasing an additional 48,967 shares during the last quarter. Hedge funds and other institutional investors own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.